BioNTech SE (LON:0A3M)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 17.26B -13.5% |
| Revenue (ttm) | 2.28B -7.9% |
| Net Income | -1.45B |
| EPS | -5.86 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 486 |
| Open | 92.75 |
| Previous Close | 92.79 |
| Day's Range | 92.04 - 93.60 |
| 52-Week Range | 79.51 - 123.69 |
| Beta | 1.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About BioNTech SE
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli... [Read more]
Financial Performance
In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
BioNTech price target lowered to $130 from $135 at Evercore ISI
Evercore ISI analyst Cory Kasimov lowered the firm’s price target on BioNTech (BNTX) to $130 from $135 and keeps an Outperform rating on the shares.
BioNTech price target raised to $142 from $138 at Canaccord
Canaccord raised the firm’s price target on BioNTech (BNTX) to $142 from $138 and keeps a Buy rating on the shares. The firm noted they lowered their Covid guidance but…
BioNTech price target lowered to $125 from $130 at Citi
Citi lowered the firm’s price target on BioNTech (BNTX) to $125 from $130 and keeps a Buy rating on the shares.
BioNTech SE Earnings Call Transcript: Q2 2026
Q2 2026 saw revenues decline year-over-year due to lower COVID-19 vaccine demand and absence of one-time revenue, while oncology pipeline advanced with multiple pivotal trials and robust clinical data. Revised 2026 guidance reflects weaker vaccine demand, but strong cash reserves and disciplined capital allocation support continued investment in late-stage assets.
BioNTech SE Earnings release: Q2 2026
BioNTech SE released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
BioNTech SE Slides: Q2 2026
BioNTech SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings
Pfizer beats earnings forecasts for the second quarter, while BioNTech's results miss expectations due to weak Covid vaccine demand.
BioNTech lowers 2026 sales outlook as COVID vaccine demand softens
German vaccine maker BioNTech lowered its full year sales outlook range on Tuesday due to softer-than-expected COVID-19 vaccine demand and the timing of milestone-related revenues.
BioNTech cuts FY26 revenue view to EUR 1.6B-EUR 1.9B from EUR 2B-EUR 2.3B
The company said, “BioNTech (BNTX) is revising its full-year 2026 financial guidance revenue range due to: COVID-19 vaccine market. Softer than anticipated global COVID-19 vaccine demand. In Germany e...
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer , taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal cli...
BioNTech says Sobi's Oelkers will replace Sahin as CEO
German biotech firm BioNTech said on Monday that Sobi's CEO Guido Oelkers will succeed Ugur Sahin as its chief executive.
BioNTech CEO Ugur Sahin to depart, Guido Oelkers to succeed
BioNTech (BNTX) announced that its supervisory board has appointed Guido Oelkers to the management board as CEO, who will take office by February 1, 2027, at the latest. Succeeding Ugur…
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
Mainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Manageme...
EC authorizes Pfizer, BioNTech XFG-adapted COVID-19 vaccine in EU
Pfizer (PFE) and BioNTech (BNTX) announced that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for a...
European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authori...
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Ad...
BioNTech price target lowered to $119 from $126 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on BioNTech (BNTX) to $119 from $126 and keeps an Overweight rating on the shares. Biotech could benefit from broader market leadership and…
BioNTech held buyer talks over four German sites set to close, Handelsblatt reports
BioNTech has held confidential talks with potential buyers about the German sites that the COVID‑19 vaccine maker plans to close, which has now grown to four locations, the Handelsblatt newspaper r...
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel tol...
BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial
BioNTech SE (BNTX) and Bristol Myers Squibb Company (BMY) announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific...
Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1...
This Biotech's Cancer Portfolio Could End Its Rough Patch
The drugmaker is looking to its oncology pipeline to drive its next leg of growth.
BioNTech upgraded to Buy from Neutral at UBS
UBS upgraded BioNTech (BNTX) to Buy from Neutral with a price target of $135, up from $117. The firm cites its increased conviction and market opportunity for the company’s oncology…
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam...
Bernstein starts BioNTech at Market Perform, sees high registration risk
Bernstein initiated coverage of BioNTech (BNTX) with a Market Perform rating and $96 price target Investors should pass on BioNTech at this time because of their aggressive pumitamig clinical developm...